Patents by Inventor Shaharyar Khan

Shaharyar Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220048865
    Abstract: The present application provides a novel phenyl derivative, 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof, which is useful for regulating mitochondria activity, reducing adiposity, treating diseases including diabetes and diabetes-associated complications.
    Type: Application
    Filed: October 28, 2021
    Publication date: February 17, 2022
    Inventor: Shaharyar Khan
  • Publication number: 20210238144
    Abstract: The present application provides a novel phenyl derivative, 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof, which is useful for regulating mitochondria activity, reducing adiposity, treating diseases including diabetes and diabetes-associated complications.
    Type: Application
    Filed: April 15, 2021
    Publication date: August 5, 2021
    Inventor: Shaharyar Khan
  • Publication number: 20200399225
    Abstract: The present application provides a novel phenyl derivative, 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof, which is useful for regulating mitochondria activity, reducing adiposity, treating diseases including diabetes and diabetes-associated complications.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 24, 2020
    Inventor: Shaharyar Khan
  • Patent number: 10618875
    Abstract: The present application provides a novel phenyl derivative, 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof, which is useful for regulating mitochondria activity, reducing adiposity, treating diseases including diabetes and diabetes-associated complications.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 14, 2020
    Assignee: Rivus Pharmaceuticals, Inc.
    Inventor: Shaharyar Khan
  • Publication number: 20190337903
    Abstract: The present application provides a novel phenyl derivative, 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof, which is useful for regulating mitochondria activity, reducing adiposity, treating diseases including diabetes and diabetes-associated complications.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 7, 2019
    Inventor: Shaharyar Khan
  • Publication number: 20180000846
    Abstract: The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).
    Type: Application
    Filed: June 13, 2017
    Publication date: January 4, 2018
    Inventors: Shaharyar Khan, Arthur Glenn Romero, Mikael C. Herlevsen
  • Patent number: 9707244
    Abstract: The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 18, 2017
    Assignee: Gencia Corporation
    Inventors: Shaharyar Khan, Arthur Glenn Romero, Mikael C. Herlevsen
  • Publication number: 20160038565
    Abstract: Compositions and methods for treating toxicity associated with exposure to radiation and side effects of treatments for hyperproliferative disorders are provided. Typically the compositions are administered in an effective amount reduce one or more adverse side effects. The side effects to be treated include, but are not limited to reduced appetite and weight loss. The methods typically include administering to a subject a composition including a protein transduction domain, a target signal, and a transcription factor A—mitochondrial polypeptide in an amount effective to inhibit, reduce or alleviate weight loss or to increase or induce appetite.
    Type: Application
    Filed: June 17, 2013
    Publication date: February 11, 2016
    Inventor: Shaharyar Khan
  • Publication number: 20160022709
    Abstract: The present invention relates to the compositions and methods for treating or alleviating conditions that affect the epidermis (e.g., wrinkles, sun damaged skin, symptoms of aged skin, or the like).
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Shaharyar Khan, Arthur Glenn Romero, Mikael C. Herlevsen
  • Publication number: 20150283233
    Abstract: Compositions and methods for inducing, enhancing, or promoting an immune response are disclosed. In some embodiments the increased immune response is against an antigen such as a tumor antigen or a viral antigen. Immune responses include activation of cytotoxic T cells to kill cells displaying the antigen. In some embodiments, the methods include contacting cells with an effective amount of a transcription factor A-mitochondrial (TFAM) fusion protein to increase expression of a Major Histocompatibility Complex I (MHC I), reduce expression of HLA-G on the surface of cells, or increase expression of one or more cytokines or chemokines Methods of treating cancer are also disclosed.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 8, 2015
    Inventor: Shaharyar Khan
  • Patent number: 8952133
    Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: February 10, 2015
    Assignee: Gencia Corporation
    Inventor: Shaharyar Khan
  • Patent number: 8927691
    Abstract: Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 6, 2015
    Assignee: Gencia Corporation
    Inventor: Shaharyar Khan
  • Patent number: 8906390
    Abstract: Compositions and methods for delivering cargo to cells are provided. One aspect provides a synthetic vesicle containing caveolin 1 or a fragment thereof in an amount effective to form lipid rafts in the vesicle. The synthetic vesicles can be used to deliver polynucleotides, proteins, therapeutic agents, or a combination thereof to specific membrane-bound compartments of a cell. In certain aspects, the synthetic vesicles can deliver cargo to cellular organelles such as mitochondria.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: December 9, 2014
    Assignee: Gencia Corporation
    Inventor: Shaharyar Khan
  • Publication number: 20140113853
    Abstract: Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.
    Type: Application
    Filed: November 18, 2013
    Publication date: April 24, 2014
    Applicant: GENCIA CORPORATION
    Inventor: Shaharyar Khan
  • Publication number: 20140045798
    Abstract: The present invention provides a compound of Formula Ia, wherein R1 is H or phosphate and the double bond is between N1 and C1 or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N1 C1, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: Gencia Corporation
    Inventor: Shaharyar Khan
  • Publication number: 20130302876
    Abstract: Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.
    Type: Application
    Filed: March 13, 2012
    Publication date: November 14, 2013
    Inventor: Shaharyar Khan
  • Patent number: 8541550
    Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: September 24, 2013
    Assignee: Gencia Corporation
    Inventor: Shaharyar Khan
  • Patent number: 8507277
    Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: August 13, 2013
    Assignee: Gencia Corporation
    Inventor: Shaharyar Khan
  • Patent number: 8470972
    Abstract: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: June 25, 2013
    Assignee: Gencia Corporation
    Inventor: Shaharyar Khan
  • Publication number: 20130072462
    Abstract: The present invention provides a compound of Formula 1a, wherein R1 is H or phosphate and the double bond is between N? and C? or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N? C?, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: August 17, 2012
    Publication date: March 21, 2013
    Applicant: Gencia Corporation
    Inventor: Shaharyar Khan